期刊文献+

氧气驱动喷射式雾化吸入布地奈德在慢性阻塞性肺疾病急性加重期治疗中的作用 被引量:5

Effect of supplementary therapy with budesonide on acute exacerbation of COPD
下载PDF
导出
摘要 目的研究氧气驱动喷射式雾化吸入糖皮质激素(布地奈德)在慢性阻塞性肺疾病急性加重期(AECOPD)中的治疗作用及临床应用价值。方法选择60例AECOPD住院患者作为研究对象,随机分为布地奈德组、甲基泼尼松龙组和对照组,对照组正规使用沙丁胺醇、特布他林、异丙托溴铵、抗生素等,布地奈德组和甲基泼尼松龙组在此治疗基础上分别联用PARI雾化泵吸入布地奈德或静脉滴注甲基泼尼松龙治疗,3组均同时进行肺功能和动脉血气分析的监测。结果布地奈德组、甲基泼尼松龙组治疗24h、72h及7d后,第1秒用力呼气容积占预计值百分和动脉血氧分压均较对照组显著改善,差异有统计学意义(P<0.05);且布地奈德组、甲基泼尼松龙组间比较无显著差异。结论PARI雾化泵吸入布地奈德可以替代静脉滴注甲基泼尼松龙治疗AECOPD。 ObjectiveTo investigate the clinical effect of supplementary therapy with budesonide on acute exacerbation of chronic obstructive pulmonary disease (COPD).MethodsSixty patients presenting with acute exacerbation of COPD were randomly divided into three groups. The control group received routine treatment, including nebulized β2agonists, ipratropium bromide, antibiotics, and supplemental oxygen. The budesonide group and the methylprednisolone group received combined therapy of routine treatment and nebulized budesonide or intravenous infusion of methylprednisolone, respectively. All patients underwent the measurement of pulmonary function and arterial blood gas analysis.ResultsThe FEV1% and blood gas parameters were more significantly improved in the budesonide group and methylprednisolone group than those in the control group, while there was no difference in FEV1% and blood gas parameters between budesonide group and methylprednisolone group.ConclusionsNebulized budesonide may be an alternative to systemic corticosteroids in the treatment of acute exacerbations of COPD.
出处 《实用老年医学》 CAS 2010年第2期150-152,共3页 Practical Geriatrics
关键词 慢性阻塞性肺疾病 布地奈德 动脉血气分析 chronic obstructive pulmonary disease budesonide arterial blood gas analysis
  • 相关文献

参考文献10

  • 1Celli BR,MacNee W.Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper[J].Eur Respir J,2004,23(6):932-946.
  • 2Maltais F,Ostinelli J,Bourbeau J,et al.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease:a randomized controlled trial[J].Am J Respir Crit Care Med,2002,165(5):698-703.
  • 3Fujimoto K,Yasuo M,Urushibata K,et al.Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease[J].Eur Respir J,2005,25(4):640-646.
  • 4Tanino M,Betsuyaku T,Takeyabu K,et al.Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema[J].Thorax,2002,57(5):405-411.
  • 5Drost EM,Skwarski KM,Sauleda J,et al.Oxidative stress and airway inflammation in severe exacerbations of COPD[J].Thorax,2005,60(4):293-300.
  • 6周新.联合吸入糖皮质激素和β_2受体激动剂治疗慢性阻塞性肺疾病[J].实用老年医学,2008,22(3):173-175. 被引量:7
  • 7Gartlehner G,Hansen RA,Carson SS,et al.Efficacy and safety of inhaled corticosteroids in patients with COPD:a systematic review and meta-analysis of health outcomes[J].Ann Fam Med,2006,4(3):253-262.
  • 8Vaghi A,Berg E,Liljedahl S,et al.In vitro comparison of nebulised budesonide (Pulimicort Respules) and beclomethasone dipropionate (Clenilper Aerosol)[J].Pulm Pharmacol Ther,2005,18(2):151-153.
  • 9Szefler SJ,Lyzell E,Fitzpatrick S,et al.Safety profile of budesonide inhalation suspension in the pediatric population:worldwide experience[J].Ann Allergy Asthma Immunol,2004,93(1):83-90.
  • 10Gunen H,Hacievliyagil SS,Yetkin O,et al.The role of ne-bulised budesonide in the treatment of exacerbations of COPD[J].Eur Respir J,2007,29(4):660-667.

二级参考文献11

  • 1Brines R, Thome M. Clinical consensus on COPD [ J ]. Respir Med: COPD Update ,2007,3 ( 2 ) :42-48.
  • 2Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease[ J]. Thorax,2005,60( 12 ) : 992-997.
  • 3Gartlehner G, Hansen RA, Carson SS,et al. Efficacy and safety of inhaled corticosteroids in patients with COPD:a systematic review and meta-analysis of health outcomes [ J ]. Ann Fam Med, 2006, 4 (3): 253-262.
  • 4Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD [ J ]. Chest ,2004,125 ( 1 ) :249-259.
  • 5Husereau D, Shukla V, Boucher M. Long acting beta 2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials [ J ]. BMC Pulm Med, 2004,4:7-17.
  • 6Barnes NC, Qiu YS,Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone Propionate in chronic obstructive lung disease [ J ]. Am J Respir Crit Care Med, 2006, 173(7) :736-743.
  • 7Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [ J ]. Eur Respir J, 2003, 22 (6): 912-919.
  • 8Calverley PM, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease :a randomised controlled trial [ J ]. Lancet, 2003,361 (9356) :449-456.
  • 9Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease [ J ]. Eur Respir J, 2003,21 ( 1 ) :74-81.
  • 10Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [ J ]. N Engl J Med, 2007, 356 (8): 775-789.

共引文献6

同被引文献42

引证文献5

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部